Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30136% above fair value
$163.81−6.48 (-3.81%)
Close on Nov 20, 2026Market cap $10.47BP/E –Yield –
Repligen market cap
Market capitalization is the share price multiplied by the number of shares outstanding.
Repligen's market cap was $9.74B on Nov 11, 2026, against $9.63B a year earlier. Over the last 5 years it ranged from $6.58B to $14.64B, with a median of $9.12B.
Market Cap at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $9.74B | +5.6% |
| 2025 | Dec 31, 2025 | $9.22B | +14.4% |
| 2024 | Dec 31, 2024 | $8.06B | -19.6% |
| 2023 | Dec 29, 2023 | $10.03B | +6.7% |
| 2022 | Dec 30, 2022 | $9.40B | -35.8% |
| 2021 | Dec 31, 2021 | $14.64B | +45.2% |
| 2020 | Dec 31, 2020 | $10.08B | +109.4% |
| 2019 | Dec 31, 2019 | $4.81B | +108.2% |
| 2018 | Dec 31, 2018 | $2.31B | +46.4% |
| 2017 | Dec 29, 2017 | $1.58B | +51.6% |
| 2016 | Dec 30, 2016 | $1.04B | +11.9% |
| 2015 | Dec 31, 2015 | $931.97M | +43.9% |
| 2014 | Dec 31, 2014 | $647.52M | +48.9% |
| 2013 | Dec 31, 2013 | $434.88M | +124.7% |
| 2012 | Dec 31, 2012 | $193.50M | +81.0% |
| 2011 | Dec 30, 2011 | $106.92M | -25.9% |
| 2010 | Dec 31, 2010 | $144.23M | – |
See a number that looks wrong?